1. Home
  2. KNDI vs JSPR Comparison

KNDI vs JSPR Comparison

Compare KNDI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kandi Technologies Group Inc

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.56

Market Cap

61.9M

ML Signal

HOLD

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.58

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
JSPR
Founded
2002
2018
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.9M
26.3M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
KNDI
JSPR
Price
$0.56
$0.58
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
73.6K
313.7K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.32
52 Week High
$1.35
$2.69

Technical Indicators

Market Signals
Indicator
KNDI
JSPR
Relative Strength Index (RSI) 36.42 44.35
Support Level N/A $0.56
Resistance Level $0.70 $1.01
Average True Range (ATR) 0.03 0.05
MACD -0.00 -0.01
Stochastic Oscillator 47.51 37.56

Price Performance

Historical Comparison
KNDI
JSPR

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: